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Introduction: Vascular-type Ehlers-Danlos syndrome is an autosomal dominant disease that causes arterial spurting,
intestinal perforation, uterine rupture and hemopneumothorax due to decreased production of type III collagen.
The average age at death is 48 years old, and it is considered to be the most severe form of Ehlers-Danlos
syndrome. We report the case of a 64-year-old Japanese woman and her 38-year-old daughter who were
diagnosed with this disease.
Case presentation: A 64-year-old Japanese woman was referred to our hospital because of right anterior chest
pain following cough and pharyngeal discomfort. Pleurisy was suspected due to the presence of right pleural
effusion, so the next day she was referred to our department, where a detailed examination led to the diagnosis of
hemothorax. The bleeding that caused the right hemothorax was difficult to control, so our patient was transferred
to the Department of Thoracic Surgery for hemostasis control. Our patient’s personal history of uterine hemorrhage
and skin ulcers, as well as the finding of skin fragility during surgery, were indicative of a weak connective tissue
disease; therefore, after improvement of the hemothorax, a genetic analysis was performed. This revealed a
heterozygous missense mutation in COL3A1, c.2411 G>T p.Gly804Val (exon 36). A detailed investigation conducted
at a later date revealed that her daughter also had the same genetic mutation. This led to the diagnosis of
vascular-type Ehlers-Danlos syndrome characterized by a new gene mutation.
Conclusion: We report a new genetic mutation associated with vascular-type Ehlers-Danlos syndrome. We present
the clinical and imaging findings, and the disease and treatment course in this patient. We believe this information
will be important in treating future cases of vascular-type Ehlers-Danlos syndrome in patients with this mutation.Introduction
Ehlers-Danlos syndrome (EDS) is used to refer to a group
of genetic disorders characterized by connective tissue
fragility caused by abnormalities affecting collagen - a mo-
lecular constituent of the extracellular matrix - as well as
its modifying enzymes [1]. EDS is classified into six differ-
ent types: classical, joint hypermobility, vascular, kyphos-
coliosis, arthrochalasia and dermatosparaxis [1]. The
vascular type (vEDS), which is considered to have the
most unfavorable prognosis, is found in one person per
50,000 to 100,000. vEDS is caused by mutations in the* Correspondence: fk_respiratory@yahoo.co.jp
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reproduction in any medium, provided the oralpha 1 type III collagen gene (COL3A1), which result in
decreased production of type III collagen [2]. Although it
is believed to be an autosomal dominant disease, half of
the affected patients reportedly have no family history,
and it is assumed that they develop the disease through
newly generated mutations [3]. So far, over 250 cases of
mutations of the COL3A1 gene have been reported, and
no particular site seems to have a high proportion of
mutations [4]. In addition, the relationship between the
site of mutation and the severity of the disease still
remains unclear [4]. The diagnosis of vEDS is based on
clinical findings and confirmed by identification of a
causative mutation in COL3A1 [1].
In this study, we report our experience with a case of
vEDS in which the diagnosis was based on clinical findings
and confirmed by genetic analysis, which showed aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Skin findings. (a) Anterior chest wall: the skin was thin
and subcutaneous veins were visible through it. (b) Back of the left
foot: pigmented scars caused by cutaneous arteriovenous fistulae
were visible.
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(exon 36), of the COL3A1 gene.
Case presentation
A 64-year-old Japanese woman experienced pharyngeal
discomfort late one night in July 2011, as well as pain in
the right anterior region of her chest while coughing. She
was brought to our hospital on the same night because
the chest pain continued. A detailed examination showed
right pleural effusion, based on which pleurisy was diag-
nosed. She was hospitalized on the day of admission and
referred to our department the next day. Her past medical
history revealed that, at the age of 26 years, she gave birth
to her first child at 36 weeks of pregnancy, and underwent
a total hysterectomy one month later because of an in-
tractable uterine hemorrhage. At the age of 49, she under-
went stripping of varicose veins of her lower extremities,
and at the age of 62 years, she was diagnosed with arterio-
venous fistulae of her lower extremities, for which she was
being treated at a nearby dermatology clinic on an out-
patient basis. She had a medical history of a skin ulcer, but
had no history of easy and extensive bruising of the skin,
enlargements of scars, or postoperative complications.
There was no family history of vEDS, and our patient did
not have a history of smoking or alcohol consumption.
The physical findings on admission were as follows:
body temperature, 35.7°C; blood pressure, 94/60mmHg;
pulse rate, regular at 67 beats/min; respiratory rate,
16 beats/min. Percutaneous monitoring of her arterial
oxygen saturation in room air showed a blood oxygen
saturation (SpO2) level of 95%. Our patient was con-
scious and lucid, and there were no abnormal findings
on her neck. There was no abnormal heart sound, but
her breathing sounds were diminished on the right side.
The site of the right chest pain was around the second
intercostal space at the right sternal border, and no ten-
derness was observed. There were no significant abdom-
inal or neurological findings. Her face was normal. Thin
subcutaneous veins were visible through the skin of the
anterior chest region (Figure 1a), and pigmented scars
due to cutaneous arteriovenous fistulae were found at
the dorsum of her left foot (Figure 1b). Premature aging
of her skin was found.
On admission, the collected blood samples showed an
erythrocyte sedimentation rate of 56mm/h and immuno-
globulin G levels that had elevated to 2025mg/dL. Her
activated partial thromboplastin time, prothrombin time,
fibrinogen level, D-dimer level and other laboratory find-
ings were normal (Table 1). A plain chest radiograph
showed a right pleural effusion (Figure 2a); chest com-
puted tomography (CT) showed pleural fluid with a CT
value of 30 to 60 Hounsfield units in the right pleural
cavity, which was accompanied by a region showing CT
values comparable to those of pleural effusion, locateddorsally from the area surrounding her right internal
thoracic artery (Figure 2b,c). An abdominal CT showed
a large number of saccular and fusiform aneurysms in
her celiac artery, splenic artery, superior mesenteric ar-
tery, right and left renal arteries, and right and left com-
mon iliac arteries (Figure 2d).
Blood samples collected eight hours after admission, at
the time of referral to our department, showed hemoglobin
levels of 9.5g/dL, and a plain chest radiograph showed an
increase in the right pleural effusion compared with the
image taken at the time of admission. Therefore, an ex-
ploratory pleural puncture was performed and a bloody
pleural effusion was obtained. A drain was inserted into her
thoracic cavity. Approximately 600mL of bloody pleural ef-
fusion was recovered during the two hours that followed
the insertion of the drain. Her lung expansion was poor, so
emergent irrigation and drainage and hemostatic surgery
were performed using thoracoscopy. Surgical findings
revealed the presence of an ecchymosis behind the medias-
tinal pleura that extended from the posterior surface of her
sternum towards her right atrium. However, the site of
bleeding, adhesions and cysts that caused the hemothorax
were not found in her lung parenchyma or chest wall.
Because the connective tissue was fragile, and the surgery
could no longer be postponed, we affixed fibrin glue to
the ecchymosis and completed the surgical procedure.
Postoperative reaccumulation of the pleural effusion was
not observed, and a blood transfusion was not required.
Table 1 Laboratory findings on admission


















Hemoglobin 11.0-15.0 11.1g/dL Fibrinogen 130-380 318mg/dL
Platelet 14.0-35.0 × 104/mm3 13.6 × 104/mm3 D-dimer 0.0-1.0 1.0μg/mL







Biochemistry smear negative negative
Lactate dehydrogenase 110-210 202IU/L culture negative negative
Creatine kinase 45-170 101IU/L Pleural effusion
Cytology class II
Serological test
C-reactive protein 0.0-0.3 0.2mg/dL Urinalysis
Immuno-globulin G(IgG) 870-1700 2025mg/dL protein ( - ) ( - )
IgG4 4.8-105 48mg/dL blood ( - ) ( - )
Carcino-embryonic antigen 0.0-5.0 0.8ng/mL
Myeloperoxidase-type anti-neutrophil cytoplasmic antibody <10 <10U/mL
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presence of a large number of aneurysms were indicative of
weak connective tissue disease. Our patient met two major
diagnostic criteria for vEDS according to Beighton et al. [1],
thin translucent skin and arterial, intestinal or uterine fra-
gility or rupture. For a definite diagnosis of vEDS, a biopsy
examination of skin from her upper right arm was per-
formed, along with analysis of the type III collagen produc-
tion capacity of cultured dermal fibroblasts and an analysis
of the COL3A1 gene. Histopathological examination of skin
tissue sections stained with hematoxylin-eosin showed nor-
mal results. An electron microscope examination revealed
that the collagen fibers were of an irregular size, which was
most marked in regions surrounding the blood vessels.
The amount of type III/I collagen had decreased by
14.7%, and a heterozygous missense mutation, c.2411 G>T
p.Gly804Val (exon 36), was found in the COL3A1 gene.
These findings confirmed the diagnosis of vEDS (Figure 3).
Approximately one month after surgery for the hemo-
thorax, our patient was transported to our emergency de-
partment because of sudden abdominal pain. The clinical
and surgical findings led to the diagnosis of acute peritonitis
due to perforation of her digestive tract. Our patient wasdischarged from the hospital one month after laparotomy
and drainage. In addition, our patient had a 38-year-old
daughter, who was single. The daughter was asymptomatic,
but we conducted the genetic tests because vEDS is an
autosomal dominant inherited disease. The results showed
that she carried the same genetic mutation as her mother.
Currently, she and her mother are being treated on an out-
patient basis.
Discussion
Approximately 98% of vEDS cases are caused by a muta-
tion in the COL3A1 gene. COL3A1 is composed of 52
exons, and is expressed in the arteries, intestines, lungs
and the uterus [5]. Mutations of this gene cause aortic
aneurysms, aortic dissection and rupture, gastrointestinal
hemorrhage and perforation, uterine rupture, pneumo-
thorax, hemothorax, and, in some cases, sudden death [4].
In most cases, because the glycine that is present in the
COL3A1 gene is substituted for other amino acids, the
generation of the normal type III collagen is inhibited, and
vEDS develops [6]. In our study, our patients also showed
a mutation in exon 36 of the COL3A1 gene. This is the
first time this heterozygous missense mutation, c.2411
Figure 2 Chest and abdominal imaging findings. (a) Plain chest radiograph: pleural effusion was found in the right hemithorax. (b) Chest
computed tomography: right pleural effusions were detected in the lung window. (c) In the mediastinal window, the right pleural effusion was
30 to 60 Hounsfield units; a low-density area (white arrow) was found around the right internal thoracic artery. (d) Abdominal computed
tomography: saccular/fusiform aneurysms (white curved arrows) were found in the celiac artery, splenic artery, superior mesenteric artery, renal
arteries and common iliac artery. Aortic dissection was found (white circle).
Figure 3 Type III collagen production capacity and analysis of the COL3A1 gene. (a) Type III collagen production capacity: the patient (P)
showed decreased expression of [α1(III)] 3 compared with the normal control (N). The production of type III/type I collagen was 14.7% of the
normal value. (b) Analysis of the COL3A1 gene: a heterozygous missense mutation characterized by GGC(Gly)→GTC(Val) was found at c. 2411
(c.2411 G>T p.Gly804Val (exon 36)). α1(I), α1 chain of type I collagen; α2(I), α2 chain of type I collagen; Gly, glycine; Glu, glutamic acid; Arg,
arginine; Thr, threonine; Pro, proline; Ala, alanine.
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this mutation, c.2411G>T p. G804V, is novel, mutation in
the same gene of the same amino acid, c.2410G>A
p.G804S, has been reported before [7].
In adults, symptoms of vEDS are mostly manifested in
the cardiovascular system, respiratory system and digest-
ive organs, where this gene is expressed, and are often
observed during pregnancy and childbirth. Arterial rup-
ture, arterial dissection and aneurysms are the cardiovas-
cular symptoms reported in 77% of patients [8]. Arterial
rupture may occur spontaneously in the thorax or abdo-
men in 50% of patients [2]. Intestinal rupture, mostly sig-
moid, has been reported in 25% of patients with vEDS [2].
Hemopneumothorax, hemoptysis and alveolar hemor-
rhage have been found in 51% of patients, and have been
reported to be the first symptom in 45% of patients [9].
Kawabata et al. previously reported that most pulmonary
lesions consist of idiopathic lung tissue lacerations [10].
Chest CT has been reported to show ground glass opacity
due to bleeding, a tumor-like shadow due to the presence
of a hematoma, a cavernous opacity following the forma-
tion of the hematoma, or a cystic shadow and a calcified
opacity [6,8,11,12]. In addition, most pleural lesions have
been reported to consist of pneumothorax and hemo-
thorax caused by weakening of the pleura and vascular
fragility [2,6,11-13]. Our patient had gastrointestinal per-
foration and hemothorax, which are very similar to the
complications associated with vEDS.
vEDS is associated with a maximal mortality risk of
12% due to uterine rupture before or after childbirth [2].
Thus, most symptoms of vEDS found in adulthood are
severe; one quarter of patients will have experienced
symptoms by the age of 20 years, and 80% of patients by
the age of 40 years. The average age at the time of death
has been reported to be 48 years [2,4]. In our case, the
bleeding following childbirth at the age of 26 years is
now believed to be caused by vEDS. Compared to the
average age at the time of death reported thus far, our
patient has a relatively long-term survival period, the
reason for which is unknown. Pepin et al. reported that
the complications of vEDS were not associated with spe-
cific mutations in COL3A1 [4]. In our case, except for
the fact that our patient was initially diagnosed at an
advanced stage, there was no particularly unusual clin-
ical phenotype.
No causal treatment for vEDS is available, and the
current treatment consists mainly of the prevention of
complications, as well as symptomatic treatment, including
surgery and catheterization [2]. Because catheterization
and surgical treatment are highly invasive [7], conservative
treatment is preferred where possible, and when sur-
gery is inevitable the procedure is performed cautiously.
The postoperative monitoring needs to be prolonged.
Any kind of elective surgery, for example, stripping ofvaricose veins, is contraindicated. Arteriograms and en-
doscopies should be avoided [14]. However, because we
unfortunately did not notice the presence of vEDS at
the time of admission, an emergent surgery for hemop-
neumothorax was performed, and our patient was con-
sequently correctly diagnosed with vEDS based on the
operative and pathological findings. At the time of the
second admission, we believe that the emergent oper-
ation was absolutely necessary to rescue this patient
from life-threatening acute peritonitis due to perfor-
ation of her digestive tract. Celiprolol has recently been
reported to be effective in the prevention of arterial
complications; it is a β1 receptor antagonist that is
widely used in the treatment of hypertension. In a report
on 53 patients with vEDS divided into a celiprolol admin-
istration group (25 patients) and a non-administration
group (28 patients), the incidence of arterial ruptures
caused by aortic dissection was 20% in the celiprolol group
and 50% in the control group, and the hazard ratio was
0.36. Celiprolol was found to have a preventive effect on
arterial rupture and aortic dissection that is brought about
via an increase in type III collagen production via trans-
forming growth factor-beta (TGFβ) stimulation or activa-
tion of intrinsic TGFβ [15]. However, the role of the TGFβ
signal pathway in the treatment of vEDS using celiprolol is
still debatable. Our patient was not given celiprolol, but
her blood pressure was consistently maintained at a lower
level. Thus, hemodynamic control may also be important
for the treatment of vEDS.
In addition, because vEDS is an autosomal dominant
inherited disorder, taking the next generation into con-
sideration is necessary. To this end, psychosocial support
and genetic counseling are of crucial importance. We
conducted a genetic test for vEDS and found that the
daughter carried the same genetic mutation as her
mother. Because of this diagnosis, a systemic search for
the lesion caused by vEDS and counseling by a specia-
lized counselor were provided to the daughter.Conclusion
The case reported in this study is valuable because of
the discovery of a new genetic mutation associated with
vEDS. We have reported the clinical and imaging find-
ings, and the disease and treatment course in our pa-
tient. We believe this data will be important in treating
future cases of patients with vEDS with this mutation.Consent
Written informed consent was obtained from both
patients for publication of this case report and accom-
panying images. A copy of the written consent is avail-
able for review by the Editor-in-Chief of this journal.
Kashizaki et al. Journal of Medical Case Reports 2013, 7:35 Page 6 of 6
http://www.jmedicalcasereports.com/content/7/1/35Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FK analyzed and interpreted the patient’s data and wrote the paper. AH
conducted the genetic analysis. AH and HO were major contributors in
writing the manuscript. KK and AY performed surgery. All authors read and
approved the final manuscript.
Acknowledgements
We thank Miki Kanno, Miyuki Funakoshi and Takashi Namatame for their
technical assistance.
Author details
1Department of Respiratory Medicine, Yokohama Municipal Citizen’s Hospital,
56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa 240-8555, Japan.
2Department of Medical Oncology, Yokohama Municipal Citizen’s Hospital,
56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa 240-8555, Japan.
3Department of Dermatology, School of Medicine, Dokkyo Medical
University, 880 Kitakobayashi, Mibu, Tochigi 321-0293, Japan. 4Department of
Thoracic Surgery, Yokohama Municipal Citizen’s Hospital, 56 Okazawa-cho,
Hodogaya-ku, Yokohama, Kanagawa 240-8555, Japan.
Received: 1 August 2012 Accepted: 28 November 2012
Published: 1 February 2013
References
1. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ: Ehlers-Danlos
syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National
Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet
1998, 77:31–37.
2. Pepin MG, Byers PH: Ehlers-Danlos syndrome, vascular type. In
GeneReviews at GeneTests: Medical Genetics Information Resource (database
online). Edited by. Seattle: University of Washington; 1993–2011. Available
from http://www.ncbi.nlm.nih.gov/books/NBK1494.
3. Watanabe A, Kosho T, Wada T, Sakai N, Fujimoto M, Fukushima Y, Shimada T:
Genetic aspects of the vascular type of Ehlers-Danlos syndrome (vEDS, EDSIV)
in Japan. Circ J 2007, 71:261–265.
4. Pepin M, Schwarze U, Superti-Furga A, Byers PH: Clinical and genetic
features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J
Med 2000, 342:673–680.
5. Watanabe A, Shimada T: Vascular type of Ehlers-Danlos syndrome. J Nihon
Med Sch 2008, 75:254–261.
6. Sadakata R, Hatamochi A, Kodama K, Kaga A, Yamaguchi T, Soma T, Usui Y,
Nagata M, Ohtake A, Hagiwara K, Kanazawa M: Ehlers-Danlos syndrome
type IV, vascular type, which demonstrated a novel point mutation in
the COL3A1 gene. Intern Med 2010, 49:1797–1800.
7. Narcisi P, Richards AJ, Ferguson SD, Pope FM: A family with Ehlers-Danlos
syndrome type III/articular hypermobility syndrome has a glycine 637 to
serine substitution in type III collagen. Hum Mol Genet 1994, 3:1617–1620.
8. Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, Kalra M,
Sullivan T, Gloviczki P: The spectrum, management and clinical outcome of
Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg 2005,
42:98–106.
9. Kosho T, Watanabe A, Morisaki H, Fukushima Y, Hatamochi A: Nationwide
survey of Ehlers-Danlos syndrome, vascular type: a preliminary study
supported by research on intractable disease of ministry of health,
welfare, and labor. Jap J Genet Counsel 2010, 31:157–161.
10. Kawabata Y, Watanabe A, Yamaguchi S, Aoshima M, Shiraki A, Hatamochi A,
Kawamura T, Uchiyama T, Watanabe A, Fukuda Y: Pleuropulmonary
pathology of vascular Ehlers-Danlos syndrome: spontaneous laceration,
haematoma and fibrous nodules. Histopathology 2010, 56:944–950.
11. Dowton SB, Pincott S, Demmer L: Respiratory complications of Ehlers-Danlos
syndrome type IV. Clin Genet 1996, 50:510–514.
12. Watanabe A, Kawabata Y, Okada O, Tanabe N, Kimura H, Hatamochi A,
Shinkai H, Sakai N, Shimada T, Hiroshima K, Kuriyama T: Ehlers-Danlos
syndrome type IV with few extrathoracic findings: a newly recognized
point mutation in the COL3A1 gene. Eur Respir J 2002, 19:195–198.
13. Ishiguro T, Takayanagi N, Kawabata Y, Matsushima H, Yoshii Y, Harasawa K,
Yamaguchi S, Yoneda K, Miyahara Y, Kagiyama N, Tokunaga D, Aoki F, Saito H,
Kurashima K, Ubukata M, Yanagisawa T, Sugita Y, Okita H, Hatamochi A:Ehlers-Danlos syndrome with recurrent spontaneous pneumothoraces
and cavitary lesion on chest X-ray as the initial complications.
Intern Med 2009, 48:717–722.
14. Germain DP: Ehlers-Danlos syndrome type IV. Orpanet J Rare Dis 2007, 2:32.
15. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL,
Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H,
Jeunemaitre X, Laurent S, Boutouyrie P: Effect of celiprolol on prevention
of cardiovascular events in vascular Ehlers-Danlos syndrome: a
prospective randomised, open, blinded-endpoints trial. Lancet 2010,
376:1476–1484.
doi:10.1186/1752-1947-7-35
Cite this article as: Kashizaki et al.: Vascular-type Ehlers-Danlos syndrome
caused by a hitherto unknown genetic mutation: a case report. Journal
of Medical Case Reports 2013 7:35.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
